Brokers Issue Forecasts for Leap Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:LPTX)

Leap Therapeutics, Inc. (NASDAQ:LPTX – Get Rating) – HC Wainwright issued their FY2027 earnings estimates for shares of Leap Therapeutics in a research note issued on Wednesday, January 18th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of $0.31 per share for the year. HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for Leap Therapeutics’ current full-year earnings is ($0.48) per share.

Leap Therapeutics (NASDAQ:LPTX – Get Rating) last posted its earnings results on Monday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02).

Several other equities research analysts have also commented on the stock. Piper Sandler cut their price target on shares of Leap Therapeutics from $4.00 to $3.00 in a report on Tuesday. Raymond James cut their price target on shares of Leap Therapeutics from $3.50 to $2.50 and set an “outperform” rating for the company in a report on Friday, November 11th. Finally, Robert W. Baird dropped their target price on shares of Leap Therapeutics to $4.00 in a report on Monday, November 21st.

Leap Therapeutics Stock Performance

Shares of NASDAQ LPTX opened at $0.72 on Thursday. The firm has a market cap of $71.21 million, a PE ratio of -1.53 and a beta of 0.59. The firm has a fifty day moving average of $0.53 and a 200 day moving average of $0.90. Leap Therapeutics has a one year low of $0.40 and a one year high of $2.57.

Institutional Investors Weigh In On Leap Therapeutics

A number of large investors have recently modified their holdings of LPTX. Private Advisor Group LLC grew its holdings in shares of Leap Therapeutics by 104.5% during the first quarter. Private Advisor Group LLC now owns 22,500 shares of the company’s stock worth $39,000 after buying an additional 11,500 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Leap Therapeutics during the 1st quarter valued at about $26,000. BlackRock Inc. boosted its position in shares of Leap Therapeutics by 1.2% during the 1st quarter. BlackRock Inc. now owns 1,198,188 shares of the company’s stock valued at $2,098,000 after acquiring an additional 14,079 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Leap Therapeutics by 4.4% during the 1st quarter. Vanguard Group Inc. now owns 3,256,331 shares of the company’s stock valued at $5,699,000 after acquiring an additional 137,159 shares during the last quarter. Finally, Silverarc Capital Management LLC boosted its position in shares of Leap Therapeutics by 1.8% during the 1st quarter. Silverarc Capital Management LLC now owns 1,032,163 shares of the company’s stock valued at $1,806,000 after acquiring an additional 18,499 shares during the last quarter. Hedge funds and other institutional investors own 37.44% of the company’s stock.

About Leap Therapeutics

(Get Rating)

Leap Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR.